EGFR and non-small cell lung carcinoma: Overexpression of EGFR is a predictive biomarker for response of advanced non-small-cell lung cancer to tyrosine kinase inhibitor gefitinib3, 4 and to first-line chemotherapy plus anti-EGFR monoclonal antibody cetuximab5.